MedImmune Announces Seven Key Promotions and...(and finally as a patentattorney over a c...)

Date:11/5/2007

and finally as a patent attorney over a course of six years. Mr. Klein-Evans holds a juris doctorate degree from Georgetown University Law Center; a master of science degree in biological sciences from Stanford University; and a bachelor of arts degree in biochemistry from Columbia University.

Mr. Tim Pearson was previously vice president, finance, and treasurer, and has been named chief financial officer, responsible for overseeing the company's financial and accounting obligations. Since joining MedImmune in 1998, Mr. Pearson has raised more than $1.6 billion in debt throughout the course of his tenure, and served as corporate secretary from 2000-2004. Previously, Mr. Pearson worked at Integrated Health Services, Inc., most recently as assistant treasurer; at CIGNA Insurance as treasury manager; and at First National Bank of Maryland as a commercial lending officer. He holds a master of science degree in finance from Loyola College; a bachelor of science degree in accounting from the University of Maryland; and a bachelor of science degree in business administration from the University of Delaware.

Mr. Paul Williams was promoted to vice president, sales operations, and is now responsible for overseeing market research and marketing operations as well as for managing core sales operations competencies. Prior to joining MedImmune, Mr. Williams was a senior director at Centocor, Inc., guiding trade sales, customer supply chain and channel strategy. Mr. Williams holds a bachelor of science degree in finance from Virginia Polytechnic Institute and State University in Blacksburg, Virginia.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca plc (LSE: AZN.L,
'/>"/>

SOURCE MedImmune, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
3. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results